M Z Koubeissi1, C L Mayor, B Estephan, S Rashid, N J Azar. 1. Department of Neurology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH 44106-5040, USA. mohamad.koubeissi@uhhospitals.org
Abstract
BACKGROUND: Lacosamide (LCM) is a novel antiepileptic drug (AED) recently approved as an adjunctive therapy in the treatment of partial seizures in adults. LCM is available in oral and intravenous formulations, has linear pharmacokinetics and a unique mechanism of action. THE AIM OF THIS STUDY: To evaluate the safety and efficacy of intravenous LCM in the treatment of nonconvulsive status epilepticus (NCSE) after failure of conventional therapy. METHODS: We retrospectively reviewed all patients with NCSE treated with LCM. We reviewed the clinical and electrographic changes before and after LCM administration. We also noted any reported side effects including electrocardiographic changes. RESULTS: We report four cases of NCSE that were refractory to conventional treatment, but readily responsive to LCM. No side effects attributable to LCM were identified. CONCLUSIONS: Intravenous LCM may be safe and efficacious as an add-on AED for the treatment of NCSE when standard therapy fails.
BACKGROUND:Lacosamide (LCM) is a novel antiepileptic drug (AED) recently approved as an adjunctive therapy in the treatment of partial seizures in adults. LCM is available in oral and intravenous formulations, has linear pharmacokinetics and a unique mechanism of action. THE AIM OF THIS STUDY: To evaluate the safety and efficacy of intravenous LCM in the treatment of nonconvulsive status epilepticus (NCSE) after failure of conventional therapy. METHODS: We retrospectively reviewed all patients with NCSE treated with LCM. We reviewed the clinical and electrographic changes before and after LCM administration. We also noted any reported side effects including electrocardiographic changes. RESULTS: We report four cases of NCSE that were refractory to conventional treatment, but readily responsive to LCM. No side effects attributable to LCM were identified. CONCLUSIONS: Intravenous LCM may be safe and efficacious as an add-on AED for the treatment of NCSE when standard therapy fails.
Authors: Estevo Santamarina; Manuel Toledo; Maria Sueiras; Miquel Raspall; Nadim Ailouti; Elena Lainez; Isabel Porta; R De Gracia; Manuel Quintana; Javier Alvarez-Sabín; Xavier Salas Puig Xavier Salas Puig Journal: J Neurol Date: 2013-12 Impact factor: 4.849
Authors: Eros Yamel Moreno Morales; Manuel Fernandez Peleteiro; Ernesto Carlo Bondy Peña; Jose Maria Domínguez Lorenzo; Elva Pardellas Santiago; Anxo Fernández Journal: Clin Drug Investig Date: 2015-07 Impact factor: 2.859
Authors: Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk Journal: Ther Adv Neurol Disord Date: 2016-11-29 Impact factor: 6.570